乌帕替尼治疗日本类风湿关节炎患者的疗效与安全性:SELECT-SUNRISE 安慰剂对照 IIb/III 期研究
该研究为日本多中心 IIb/III 期剂量探索试验,纳入对传统合成 DMARD 反应不佳的活动性 RA 患者,随机接受乌帕替尼 7.5、15、30 mg 每日一次或安慰剂治疗 12 周。结果显示乌帕替尼各剂量组 ACR20 应答率显著高于安慰剂,15 mg 剂量获益风险比最佳,安全性与既往研究一致。
要点
- 乌帕替尼 7.5、15、30 mg 组第 12 周 ACR20 应答率分别为 75.5%、83.7%、80.0%,均显著高于安慰剂组的 42.9%。
- ACR50、ACR70 及 DAS28-CRP 缓解率在乌帕替尼组显著高于安慰剂,15 或 30 mg 组数值上高于 7.5 mg 组。
- 不良事件及感染在乌帕替尼组更常见,30 mg 组数值最高,未报告静脉血栓栓塞事件。
核心结论
- 乌帕替尼对 csDMARD 反应不佳的日本 RA 患者有效,安全性与既往乌帕替尼 RA 研究一致,15 mg 剂量获益风险比最佳。
研究设计与样本
- 日本多中心、IIb/III 期、剂量探索研究,患者在接受稳定 csDMARD 基础上随机接受乌帕替尼 7.5、15、30 mg 每日一次或安慰剂治疗 12 周双盲。
- 共 197 例患者接受治疗,187 例完成双盲期。
主要发现
- 第 12 周 ACR20 应答率:乌帕替尼 7.5 mg 组 75.5%、15 mg 组 83.7%、30 mg 组 80.0%,安慰剂组 42.9%(P < 0.001)。
- 乌帕替尼组在 ACR50、ACR70 及 DAS28-CRP <2.6 应答率上显著高于安慰剂组,15 或 30 mg 组数值上高于 7.5 mg 组。
- 不良事件和感染(严重感染、机会性感染、带状疱疹)在乌帕替尼组比安慰剂组更常见,30 mg 组数值最高。
- 未报告静脉血栓栓塞事件。
关键数值与推荐
- 主要终点为第 12 周 ACR20 应答率(采用无应答者填补法)。
- 关键次要终点包括 ACR50、ACR70、DAS28-CRP 缓解(<2.6)和低疾病活动度。
临床怎么用
- 对于 csDMARD 反应不佳的日本 RA 患者,乌帕替尼 15 mg 每日一次可作为获益风险比最佳的剂量选择。
- 使用乌帕替尼时需关注感染风险,尤其是 30 mg 剂量下不良事件和感染数值更高。
局限性
- 研究仅纳入日本患者,双盲期为 12 周,长期安全性和疗效未在本文报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate upadacitinib efficacy and safety dose response in Japanese patients with active RA and an inadequate response to conventional synthetic DMARDs (csDMARDs). METHODS: This was a multicentre, phase IIb/III, dose-ranging study conducted in Japan, in which patients on previously stable csDMARDs were randomized to receive upadacitinib 7.5, 15 or 30 mg once daily or matching placebo for a 12-week double-blind period. The primary endpoint was a 20% improvement in ACR criteria (ACR20) response at week 12 using non-responder imputation. Key secondary endpoints included ACR50, ACR70 and 28-joint DAS with CRP (DAS28-CRP) remission and low disease activity. Adverse events were also assessed. RESULTS: Of 197 patients treated, 187 completed the double-blind period. At week 12, more patients receiving upadacitinib 7.5, 15 or 30 mg vs placebo met the ACR20 response (75.5%, 83.7%, 80.0% vs 42.9%; P < 0.001), with significant differences observed as early as week 1. Stringent responses, including ACR50, ACR70 and DAS28-CRP <2.6, were achieved by significantly higher proportions of patients on upadacitinib than placebo and by numerically higher proportions on upadacitinib 15 or 30 mg vs upadacitinib 7.5 mg. Adverse events and infections (serious infections, opportunistic infections and herpes zoster) were more common with upadacitinib vs placebo and numerically highest with upadacitinib 30 mg. There were no venous thromboembolic events reported. CONCLUSION: Efficacy of upadacitinib was demonstrated in this population of Japanese patients with RA and an inadequate response to csDMARDs. Safety and tolerability were consistent with other upadacitinib RA studies. The 15 mg dose of upadacitinib showed the most favourable benefit-risk profile. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02720523.
引用
- Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology (Oxford). 2020. PMID: 32277824. doi:10.1093/rheumatology/keaa084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。